Standout Papers

Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapie... 2007 2026 2013 2019 642
  1. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer (2007)
    Maurizio Scaltriti, Federico Rojo et al. JNCI Journal of the National Cancer Institute
  2. NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations (2008)
    Violeta Serra, Ben Markman et al. Cancer Research
  3. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer (2016)
    María Teresa Herrera-Abreu, Marta Palafox et al. Cancer Research

Immediate Impact

2 by Nobel laureates 16 from Science/Nature 72 standout
Sub-graph 1 of 18

Citing Papers

Deubiquitinases in cancer
2023 Standout
Endocytosis in cancer and cancer therapy
2023 Standout
35 intermediate papers

Works of Marta Guzmán being referenced

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
2018
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
2008
and 7 more

Author Peers

Author Last Decade Papers Cites
Marta Guzmán 2754 2205 1078 1269 30 4.3k
Neil L. Spector 3480 2126 1421 1049 81 5.1k
Monica R. Maiello 2115 2326 539 1111 40 4.3k
Tona M. Gilmer 3714 3953 1019 1211 59 6.7k
Sarah Bacus 3500 2800 1458 785 66 5.4k
Zhen Fan 3015 2492 840 1424 70 5.5k
Mark S. Berger 4535 2237 2021 1213 67 6.8k
Ralf Brandt 2471 1867 628 1063 27 4.0k
Youngchul Song 2984 2959 507 2639 18 5.4k
Teemu T. Junttila 2396 1560 1622 729 32 3.6k
Maarit Bärlund 2188 3114 623 716 26 4.9k

All Works

Loading papers...

Rankless by CCL
2026